Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
144.00    -1.00 (-0.69%)
Bid:
144.00
Ask:
145.00
Spread: 1.00 (0.694%)
Market Cap: £113.00m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Trading Statement

19 Jan 2012 07:00

RNS Number : 8017V
Xaar PLC
19 January 2012
 



 

 

 

FOR IMMEDIATE RELEASE

19 January 2012

 

 

 

Xaar plc

 

 

YEAR END TRADING UPDATE

 

 

Xaar plc ("Xaar" or "the Group" or "the Company"), the inkjet printing technology group headquartered in Cambridge, announces an update on trading for the year ended 31 December 2011.

 

Trading for the fourth quarter of the year was slightly ahead of the Board's expectations, leading to a strong performance for the full year 2011.

 

Xaar expects to announce revenue of approximately £69 million for 2011, an increase of over 25% compared to 2010 (£54.7 million).

 

Revenue growth in 2011 was achieved mainly by increased sales into the industrial segment. Demand for Xaar's technology in this segment is principally driven by the conversion of ceramic tile printing to digital inkjet from analogue processes. During the year, Xaar made good progress with the capacity expansion programme to support this demand and the programme remains on track to continue to deliver the planned incremental capacity during the first half of 2012.

 

As expected, product sales into the graphic arts segment declined in 2011 by approximately 15% compared to 2010. As previously described, this decline reflects market maturity and competitive pressure.

 

The Group continues to maintain a strong balance sheet with net cash at 31 December 2011 of £17.4 million (30 June 2011 - £20.6 million; 31 December 2010 - £22.0 million).

 

The detailed results for 2011 are expected to be announced on 20 March 2012.

 

Board changes

 

As previously announced Phil Eaves, Sales and Marketing Director, informed the Company in 2011 of his intention to retire from full time employment in June 2012. Following an extensive search process, the Company is pleased to announce that Richard Barham has been appointed Sales and Marketing Director and member of the Xaar board with effect from 5 March 2012. After completion of a handover period, Phil Eaves will continue to support the Company in a consultant role until 30 June 2012.

 

Ian Dinwoodie, Chief Executive commented:

 

'On behalf of everyone at Xaar, I would like to thank Phil for his efforts and contribution over the last 7 years during which our revenues have grown significantly. We all wish him well for the future.

 

I am pleased to welcome Richard to the Board, who brings a wealth of experience gained through 25 years spent in numerous sectors of the Imaging and Printing industries.'

Since 1986, Mr Barham has held a range of sales, marketing and management positions at Agfa Graphics NV, where most recently, since February 2008, he acted as Vice President of the Inkjet Division where he was responsible for turning the business around and integrating a major acquisition.

 

There is no further information concerning Mr Barham which requires disclosure under rule 9.6.13 of the UK Listing Authority Listing Rules.

 

 

END

 

CONTACTS

 

Xaar plc:

01223-423663

Ian Dinwoodie, Chief Executive

www.xaar.com

Alex Bevis, Finance Director

Singer Capital Markets Limited:

020-3205-7500

Shaun Dobson

Bankside Consultants:

Simon Bloomfield

020-7367-8888 / 07771-758517

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDVLFFLFFFBBB
Date   Source Headline
1st Jul 20221:10 pmRNSTotal Voting Rights
21st Jun 20225:20 pmRNSDirector Declaration - Additional Directorship
1st Jun 202210:22 amRNSTotal Voting Rights
25th May 20221:57 pmRNSResult of AGM
3rd May 20225:20 pmRNSTotal Voting Rights
7th Apr 20226:31 pmRNSPDMR Shareholding
7th Apr 20222:50 pmRNSGrant of Options and Deferred Bonus Share Awards
1st Apr 202210:48 amRNSTotal Voting Rights
29th Mar 20227:00 amRNS2021 Full Year Results
28th Mar 202210:44 amRNSHolding(s) in Company
21st Mar 202212:37 pmRNSNotice of 2021 Preliminary Results
3rd Mar 20227:00 amRNSAcquisition of Megnajet
1st Mar 20225:29 pmRNSTotal Voting Rights
1st Feb 20225:00 pmRNSTotal Voting Rights
18th Jan 20224:35 pmRNSPrice Monitoring Extension
13th Jan 20227:00 amRNSTrading Update
4th Jan 20222:39 pmRNSBlock listing Interim Review
4th Jan 20222:37 pmRNSTotal Voting Rights
10th Dec 20214:23 pmRNSGrant of Awards - Replacement
6th Dec 202112:25 pmRNSHolding(s) in Company
1st Dec 20215:00 pmRNSTotal Voting Rights
5th Nov 202110:30 amRNSGrant of Sharesave Options
1st Nov 20214:11 pmRNSCompletion of Divestment of Xaar 3D
1st Nov 20211:56 pmRNSTotal Voting Rights
29th Oct 20214:41 pmRNSSecond Price Monitoring Extn
29th Oct 20214:36 pmRNSPrice Monitoring Extension
25th Oct 202110:38 amRNSResult of General Meeting
15th Oct 202111:50 amRNSGrant of Options and Deferred Bonus Share Awards
14th Oct 20218:44 amRNSBlock Listing Application
13th Oct 20212:52 pmRNSHolding(s) in Company
6th Oct 20212:43 pmRNSPublication of Circular and Notice of GM
6th Oct 20217:00 amRNSProposed divestment of Xaar 3D
1st Oct 202111:59 amRNSTotal Voting Rights
14th Sep 20217:00 amRNS2021 Interim Results
3rd Sep 202112:59 pmRNSNotice of 2021 Interim Results
2nd Sep 20213:40 pmRNSTotal Voting Rights
2nd Aug 20215:02 pmRNSTotal Voting Rights
22nd Jul 20217:00 amRNSTrading Update
12th Jul 20217:00 amRNSAcquisition of FFEI
1st Jul 20213:20 pmRNSBlock listing Interim Review
1st Jul 202110:51 amRNSTotal Voting Rights
22nd Jun 20215:37 pmRNSHolding(s) in Company
22nd Jun 202111:44 amRNSHolding(s) in Company
16th Jun 20211:17 pmRNSResult of AGM
1st Jun 202110:10 amRNSTotal Voting Rights
17th May 20219:27 amRNSHolding(s) in Company
12th May 202110:15 amRNSHolding(s) in Company
4th May 20213:01 pmRNSTotal Voting Rights
30th Apr 20216:23 pmRNSAnnual Financial Report
27th Apr 20217:00 amRNS2020 FULL YEAR RESULTS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.